CannTrust is the First and Only Licensed Producer approved to ship to Denmark
VAUGHAN, ON, Sept. 18, 2018 /PRNewswire/ – CannTrust Holdings Inc. ("CannTrust" or the "Company") (TSX :TRST ), one of Canada's leading and most trusted licensed producers of cannabis, today announced that it has completed its first shipment of cannabis oils to Danish Joint Venture Partner STENOCARE. With this groundbreaking shipment, CannTrust and STENOCARE are changing the face of medicine in Denmark by offering the first and only medical cannabis oils to be accepted onto the Danish Medicine List by the Danish Medicine Agency.
CannTrust's cannabis oils are now available to patients in Denmark and provide a new option outside of cannabis tea, which has been the only cannabis product available in the Danish market to date. Since medical cannabis became legal in Denmark on January 1, 2018, physicians and patients have been anxiously awaiting the introduction of cannabis oil products, as they are indicated in Denmark for the management of multiple sclerosis, chronic pain, and nausea due to the side effects of chemotherapy.
"This first shipment of CannTrust products to STENOCARE marks an important advancement of medical cannabis in Denmark and is just the beginning of many shared successes for our two companies. It also signals a significant step in CannTrust's international expansion. As more and more countries around the world accept and approve the use of medical cannabis, Denmark is a shining example of how CannTrust's expertise and pharmaceutical approach make us a strong global partner," said Brad Rogers, President, CannTrust.
"This is a historic milestone for STENOCARE, as the Danish quality requirements for safe and uniform products are some of the strictest in the world. Thanks to CannTrust's consistent quality and standardized products, we are the first in Denmark to have cannabis oil products approved for the market, and we are thrilled to be able to provide Danish patients with another therapeutic option. We look forward to working with CannTrust on the next phase of our development," says Thomas S. Schnegelsberg, CEO of STENOCARE.
The shipment advances the first phase of the STENOCARE strategy which is to import and distribute quality products from CannTrust.
Together, STENOCARE and CannTrust are leading the industry in Denmark. CannTrust first announced the Joint Venture with STENOCARE in March 2018. STENOCARE, a first-mover in Denmark's legalization of medical cannabis, has supply agreements with two of Denmark's leading pharmaceutical distributors, who together service 99% of pharmacies in the country.
Since its inception in 2014, CannTrust has led the Canadian market in producing a standardized product.
As a federally regulated licensed producer, CannTrust brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. CannTrust currently operates the recently completed 250,000 sq. ft. Phase One redevelopment of its 450,000 sq. ft. Niagara Perpetual Harvest Facility. The 200,000 sq. ft. Phase Two redevelopment is expected to be operational in the third quarter and the projected 600,000 sq. ft. greenhouse expansion has begun and is fully funded. The industry's broadest product portfolio is prepared and packaged at the 60,000 sq. ft. manufacturing centre of excellence in Vaughan, Ontario.
CannTrust is committed to research and innovation, as well as contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis. Our product development teams along with our exclusive global pharma partner, Apotex Inc., are diligently innovating and developing products that will make it easier for patients to use medical cannabis. We support ongoing patient education about medical cannabis and have a compassionate use program to support patients with financial needs.
& Keep Up to Date
Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!